List of Excipients in Branded Drug DEPO-ESTRADIOL

Generic Drugs Containing DEPO-ESTRADIOL

Company	Ingredient	NDC	Excipient
Pharmacia & Upjohn Company LLC	estradiol cypionate	0009-0271	CHLOROBUTANOL
Pharmacia & Upjohn Company LLC	estradiol cypionate	0009-0271	COTTONSEED OIL
Physicians Total Care Inc	estradiol cypionate	54868-1729	COTTONSEED OIL

What are the Most Frequently-Used Excipients in DEPO-ESTRADIOL?

# Of NDCs	Excipient
1	CHLOROBUTANOL
2	COTTONSEED OIL

Depo-Estradiol Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 14, 2026

Depo-Estradiol is an oil-based intramuscular injection of estradiol cypionate. Its commercial opportunity is primarily a formulation and supply-chain play, not a conventional small-molecule patent play. The core product uses a simple depot system based on cottonseed oil with benzyl alcohol, while the largest opportunities are preservative-free presentation, alternative oil vehicles, prefilled delivery, improved injection usability, and reliable generic supply. The product’s long-established active ingredient and dosage form limit broad composition-of-matter protection.

What is Depo-Estradiol and how is it formulated?

Depo-Estradiol contains estradiol cypionate, a long-acting ester of estradiol administered by intramuscular injection. The labeled strengths are 5 mg/mL and 10 mg/mL. The formulation is an oily depot intended to release estradiol after intramuscular administration (FDA, n.d.-a).

Product attribute	Depo-Estradiol profile
Active ingredient	Estradiol cypionate
Dosage form	Intramuscular injection
Labeled strengths	5 mg/mL and 10 mg/mL
Primary vehicle	Cottonseed oil
Preservative	Benzyl alcohol is identified in product information
Administration	Intramuscular
Release mechanism	Depot dissolution and ester hydrolysis
Approved therapeutic context	Estrogen replacement for specified hypoestrogenic conditions
Typical dosing concept	Repeat dosing at multiweek intervals, determined by clinical response
Drug category	Estrogen hormone
Controlled-substance status	Not scheduled under the federal Controlled Substances Act

The excipient system is commercially important because it controls viscosity, syringeability, depot persistence, chemical stability, local tolerability, and container compatibility. A change to the oil vehicle or preservative concentration can alter the pharmacokinetic profile and may require a new regulatory bridge.

What excipients are used in Depo-Estradiol?

The marketed formulation is based on estradiol cypionate dissolved in cottonseed oil, with benzyl alcohol identified as an inactive ingredient or preservative in product information. Exact quantitative excipient composition should be taken from the current approved labeling and product specifications rather than inferred from the qualitative ingredient listing.

The formulation has several practical characteristics:

• Cottonseed oil provides a hydrophobic depot vehicle.
• Benzyl alcohol supports antimicrobial preservation in a multidose or preserved presentation.
• The oil system avoids aqueous suspension technology.
• The esterified active ingredient reduces the need for an advanced polymeric controlled-release matrix.
• The product requires attention to viscosity at the point of administration.
• The oily formulation creates compatibility requirements for elastomeric closures, syringes, needles, and transfer devices.

The FDA Inactive Ingredient Database can support excipient precedent analysis, but precedent in another injectable product does not automatically establish suitability for an estradiol cypionate depot formulation (FDA, n.d.-b).

What excipient strategy is most attractive for Depo-Estradiol?

The strongest strategy is to preserve the established depot behavior while improving administration, safety, or manufacturing reliability. A direct substitution that changes only the oil is unlikely to create a durable commercial moat unless it produces a measurable clinical or operational advantage.

Which oil vehicles could replace cottonseed oil?

Potential alternatives include medium-chain triglyceride oil, sesame oil, castor oil, refined vegetable oils, and other parenteral-grade nonaqueous vehicles. Each candidate must be assessed for:

1. Solubility of estradiol cypionate at both labeled strengths.
2. Viscosity and injection force across storage and use temperatures.
3. Hydrolytic and oxidative stability.
4. Extractables and leachables.
5. Local tissue tolerability.
6. Compatibility with glass, cyclic olefin polymers, elastomers, and needle systems.
7. Impact on depot residence time and estradiol exposure.
8. Supply continuity and pharmacopeial quality.

Medium-chain triglyceride oil is commercially attractive because it can offer more consistent sourcing and potentially lower viscosity than some vegetable oils. It would not automatically be interchangeable with cottonseed oil. A vehicle change could alter absorption sufficiently to require comparative pharmacokinetic or clinical data.

Is a preservative-free Depo-Estradiol formulation commercially viable?

A preservative-free single-dose vial or prefilled syringe is one of the clearest differentiated opportunities. It could reduce concerns associated with benzyl alcohol exposure and improve positioning for patients requiring repeated administration.

The trade-offs include:

• Higher packaging cost.
• Greater demand for aseptic manufacturing.
• More stringent container-closure integrity requirements.
• Potentially shorter in-use flexibility.
• Need for single-dose packaging and waste controls.
• Possible regulatory classification as a new formulation rather than a routine generic equivalent.

The opportunity is strongest if paired with a prefilled syringe, low-force needle system, or home-administration workflow. A preservative-free vial alone would offer limited differentiation unless the target market values preservative avoidance.

What formulations are protected by Depo-Estradiol patents?

The public product label does not identify a contemporary patent estate protecting the basic estradiol cypionate-in-oil formulation. Estradiol cypionate and the conventional oily intramuscular dosage form are legacy technologies. Any original composition, formulation, or use patents associated with the product would be expected to have expired given the product’s long history.

Protection category	Current strategic assessment
Estradiol cypionate composition	Legacy protection; no meaningful new-product exclusivity expected
Cottonseed-oil formulation	Legacy formulation concept; weak basis for current exclusivity
Benzyl-alcohol-preserved formulation	Likely difficult to protect broadly
Alternative oil vehicle	Potentially patentable only with specific composition and demonstrated performance
Preservative-free presentation	Possible formulation or packaging claims
Prefilled syringe	Potential device, packaging, or combination-product claims
Injection-force reduction	Possible device or formulation claims
Manufacturing process	Potential process claims if technically distinct and reproducible
Method of use	Possible only for a new, specific, and non-obvious clinical use
Long-acting delivery system	Potentially patentable if it materially changes release and clinical performance

A new patent position would need to focus on a defined formulation, delivery system, manufacturing process, or treatment protocol. Broad claims covering “estradiol cypionate in an oil” would face substantial prior-art and obviousness risk.

When does Depo-Estradiol lose exclusivity?

Depo-Estradiol’s principal exclusivity has already elapsed as a practical commercial matter. The product is based on an old active ingredient, an established ester, and a conventional injectable dosage form. Current market access depends more on FDA approval, manufacturing capacity, product listing, and supply reliability than on a surviving pioneer patent.

The relevant regulatory questions are:

• Whether the reference product remains listed as the applicable reference standard.
• Whether the product is currently marketed and available for reference-product comparison.
• Whether an applicant can use the ANDA pathway.
• Whether a 505(b)(2) application is more appropriate because of formulation, vehicle, strength, or delivery differences.
• Whether any unexpired Orange Book patents or regulatory exclusivities are listed against the reference product.

The FDA Orange Book is the controlling source for current listed patents, exclusivity, and reference-product status. The absence of patent information in the prescribing information does not by itself establish the absence of Orange Book listings (FDA, n.d.-c).

What is the Orange Book and Paragraph IV status of Depo-Estradiol?

No current Paragraph IV dispute is established by the product label or the general historical profile of Depo-Estradiol. Paragraph IV risk would arise only if an ANDA applicant certified that an Orange Book-listed patent was invalid, unenforceable, or not infringed.

For this legacy product, the more probable regulatory scenarios are:

Scenario	Commercial implication
ANDA against an active reference product	Lowest regulatory complexity if pharmaceutical equivalence can be demonstrated
505(b)(2) with a new oil vehicle	Greater development flexibility but higher clinical and CMC burden
Preservative-free product	Potentially differentiated, but may require additional comparability work
Prefilled syringe	Combination-product and device validation requirements
New depot-release formulation	Possible clinical or pharmacokinetic bridging requirements
Reference product unavailable	Greater uncertainty over pathway and bioequivalence strategy

Generic applicants should not assume that an old product has no regulatory barriers. Injectable products face sterility, particulate, extractables, container-closure, stability, and local-tolerance requirements that can delay approval even when patent risk is low.

How strong is the Depo-Estradiol patent estate?

The patent estate is weak as a barrier to generic entry and potentially moderate for narrowly drafted improvement patents.

Core estate

The core product has several characteristics that reduce patent strength:

• Old active ingredient and ester technology.
• Conventional oil-based intramuscular delivery.
• No dependence on a complex polymeric delivery platform.
• Limited formulation complexity.
• Mature prior art covering estrogen esters and injectable oil vehicles.

Improvement estate

A new entrant could seek patents around:

• A defined non-cottonseed oil composition.
• A specific estradiol cypionate concentration and viscosity range.
• Reduced injection force.
• A preservative-free multidose or single-dose architecture.
• A prefilled syringe with a validated needle and elastomer system.
• A manufacturing process that controls particle burden, degradation products, or ester conversion.
• A formulation with a defined pharmacokinetic profile.
• A lower-volume injection with equivalent exposure.
• A combination of estradiol cypionate and a specific stabilizer or antioxidant.

The strongest claims would require analytical and clinical evidence showing an unexpected result, such as materially lower injection force, improved stability, lower degradation, reduced pain, or equivalent exposure at a lower injection volume.

What FDA regulatory pathway applies to new Depo-Estradiol products?

A conventional generic injectable would generally seek approval through an ANDA if the applicant can demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for the product type. A formulation using a different vehicle, preservative system, strength, route, or delivery technology may require a 505(b)(2) application.

The FDA’s 505(b)(2) pathway can be commercially useful when the product relies partly on FDA findings for an approved drug but introduces a meaningful change. The applicant may need additional nonclinical, clinical pharmacology, or clinical data depending on the change (FDA, 2019).

Key CMC workstreams include:

• Assay and related substances.
• Estradiol cypionate identity and purity.
• Ester hydrolysis and degradation monitoring.
• Sterility and bacterial endotoxin testing.
• Particulate matter.
• Container-closure integrity.
• Viscosity and injection force.
• In-use stability.
• Photostability and oxidation.
• Extractables and leachables.
• Comparative pharmacokinetics.
• Local tolerability.

What commercial opportunities exist for Depo-Estradiol?

1. Reliable generic supply

The most immediate opportunity is a dependable generic version in both 5 mg/mL and 10 mg/mL strengths. Estradiol cypionate injectables can experience supply sensitivity because the product requires sterile nonaqueous manufacturing and has a narrower supplier base than oral estrogen products.

A manufacturer with excess sterile fill-finish capacity could compete on:

• Consistent availability.
• Dual-source raw materials.
• Smaller minimum order quantities.
• Hospital and clinic contracting.
• National wholesaler coverage.
• Backup supply for specialty pharmacies.

2. Preservative-free single-dose presentation

A preservative-free vial or prefilled syringe could target patients and clinicians seeking to avoid benzyl alcohol. The commercial case strengthens when the product reduces preparation steps or supports administration outside a clinic.

3. Prefilled syringe and administration system

A prefilled syringe can reduce preparation errors, limit vial access, and improve dose consistency. The product must address oil viscosity, needle gauge, injection force, storage orientation, and device compatibility.

The device itself may create a more defensible patent position than the active ingredient. Combination-product claims should cover the specific syringe, closure, needle, fill volume, and administration parameters rather than rely on broad claims to estradiol cypionate delivery.

4. Lower-volume or lower-force injection

A more concentrated formulation could reduce injection volume, but concentration changes can affect solubility, precipitation, local irritation, and release. A lower-force formulation could improve usability for clinicians and potentially support home administration.

5. Alternative patient segments

Potential commercial segments include estrogen replacement, specialist hormone clinics, and gender-affirming care. The approved label must govern promotional claims. Use in gender-affirming therapy may occur in clinical practice, but the commercial strategy must distinguish labeled indications from off-label use.

6. Contract manufacturing and licensing

Licensing opportunities may involve:

• A sterile injectable manufacturer seeking a hormonal product.
• A specialty pharmaceutical company with endocrinology or women’s-health distribution.
• A device company with prefilled syringe technology.
• A regional partner with access to hormone clinics.
• A supplier with qualified nonaqueous injectable manufacturing.

The most valuable asset would likely be a package combining formulation know-how, validated sterile manufacturing, and a differentiated delivery device.

How does Depo-Estradiol compare with competing estradiol products?

Product type	Delivery	Main advantage	Main limitation
Estradiol cypionate injection	Intramuscular depot	Infrequent dosing and established technology	Injection burden and sterile supply complexity
Estradiol valerate injection	Intramuscular depot	Established injectable alternative	Similar injection and supply constraints
Oral estradiol	Oral	Low manufacturing complexity and broad availability	Daily dosing and first-pass exposure
Transdermal estradiol	Patch, gel, or spray	Avoids intramuscular injection and reduces first-pass exposure	Adhesion, skin transfer, and adherence issues
Estradiol implants	Subcutaneous depot	Long duration	Procedure-based administration and limited flexibility
Compounded injectable estradiol	Variable	May fill supply gaps	Quality, consistency, and regulatory limitations

Depo-Estradiol competes on dosing interval and familiarity. It loses on convenience against transdermal products and on manufacturing simplicity against oral products. Its best commercial position is a reliable, easy-to-administer injectable with stable supply and improved presentation.

What generic entry risks exist?

Generic entry risk is high because the core technology is mature and likely has limited surviving patent protection. The main barriers are technical and commercial:

• Sterile nonaqueous fill-finish capability.
• Reliable estradiol cypionate sourcing.
• Demonstration of comparable exposure.
• Management of viscosity and injection force.
• Stability in the final container.
• Market size relative to manufacturing complexity.
• Reimbursement and wholesaler access.
• Potential disruption from compounded alternatives.

A generic launch could produce price pressure without eliminating the opportunity for a differentiated product. A preservative-free or prefilled product may support premium pricing if it delivers measurable workflow or tolerability benefits.

Key Takeaways

• Depo-Estradiol is an estradiol cypionate oil-based intramuscular depot injection.
• The core formulation uses cottonseed oil and benzyl alcohol, subject to confirmation in current approved product labeling.
• Core composition and dosage-form protection are legacy assets with limited current exclusivity value.
• The strongest commercial opportunities are reliable generic supply, preservative-free packaging, prefilled syringes, alternative oil vehicles, and reduced injection force.
• A vehicle change may require a 505(b)(2) strategy rather than a straightforward ANDA.
• Improvement patents should target defined formulation, device, process, or pharmacokinetic attributes.
• The main barriers are sterile manufacturing, stability, container compatibility, and clinical comparability rather than pioneer patent litigation.
• Generic entry risk is high, but differentiated delivery systems can support a defensible specialty product.

FAQs

Can benzyl alcohol be removed from Depo-Estradiol?

Yes, a preservative-free presentation is technically possible, but it would require a suitable single-dose container or a validated multidose preservation strategy. The change could affect regulatory pathway, stability, packaging, and in-use handling.

Is cottonseed oil essential to estradiol cypionate injection?

No. Cottonseed oil is an established vehicle, not the only technically possible vehicle. Any substitute must demonstrate solubility, stability, injection performance, local tolerability, and comparable drug release.

Can a new Depo-Estradiol formulation receive new patents?

Yes, but broad claims to estradiol cypionate in oil would face substantial prior-art risk. Narrow claims covering a defined vehicle, concentration, device, manufacturing process, or demonstrated pharmacokinetic advantage are more plausible.

Is Depo-Estradiol suitable for a prefilled syringe?

Potentially. The principal development issues are oil viscosity, injection force, syringe and elastomer compatibility, storage stability, needle selection, and dose accuracy.

Does Depo-Estradiol have biosimilar risk?

No. Biosimilar rules apply to biological products. Estradiol cypionate is a chemically synthesized small molecule, so competitive risk arises from generic or 505(b)(2) products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.-a). Depo-Estradiol prescribing information: Estradiol cypionate injection. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Inactive Ingredient Database. FDA.

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2). FDA Guidance for Industry.